Fulcrum Therapeutics Inc (FULC) concluded trading on Thursday at a closing price of $4.00, with 7.63 million shares of worth about $30.52 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -57.72% during that period and on September 26, 2024 the price saw a gain of about 15.27%. Currently the company’s common shares owned by public are about 61.92M shares, out of which, 52.73M shares are available for trading.
Stock saw a price change of 15.94% in past 5 days and over the past one month there was a price change of -54.83%. Year-to-date (YTD), FULC shares are showing a performance of -40.74% which decreased to -9.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.87 but also hit the highest price of $13.70 during that period. The average intraday trading volume for Fulcrum Therapeutics Inc shares is 1.71 million. The stock is currently trading -32.78% below its 20-day simple moving average (SMA20), while that difference is down -48.20% for SMA50 and it goes to -49.05% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fulcrum Therapeutics Inc (NASDAQ: FULC) currently have 61.92M outstanding shares and institutions hold larger chunk of about 82.08% of that.
The stock has a current market capitalization of $249.60M and its 3Y-monthly beta is at 2.24. It has posted earnings per share of -$0.35 in the same period. It has Quick Ratio of 22.07 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FULC, volatility over the week remained 12.90% while standing at 10.44% over the month.
Stock’s fiscal year EPS is expected to rise by 82.18% while it is estimated to decrease by -334.51% in next year. EPS is likely to grow at an annualized rate of 16.40% for next 5-years, compared to annual growth of 1.09% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on September 13, 2024 offering a Neutral rating for the stock and assigned a target price range of between $17 and $4 to it. On September 12, 2024, RBC Capital Mkts Downgrade their recommendations, while on September 12, 2024, Leerink Partners Downgrade their ratings for the stock with a price target of $4. Stock get a Neutral rating from Cantor Fitzgerald on September 12, 2024.
